Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
A Phase III, Randomized, Controlled, Open-Label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-Boosted HIV-1 Protease Inhibitor Regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-Infected Adults Experiencing Virological Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- GSK Clinical Trials Call Center
-
-
Victoria
-
Carlton, Victoria, Australia, 3053
- GSK Clinical Trials Call Center
-
-
-
-
-
Brussels, Belgium, 1000
- GSK Clinical Trials Call Center
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 2C7
- GSK Clinical Trials Call Center
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- GSK Clinical Trials Call Center
-
Ottawa, Ontario, Canada, K1N 6N5
- GSK Clinical Trials Call Center
-
Toronto, Ontario, Canada, M4T 3A7
- GSK Clinical Trials Call Center
-
Toronto, Ontario, Canada, M5B 1L6
- GSK Clinical Trials Call Center
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 5B1
- GSK Clinical Trials Call Center
-
Montreal, Quebec, Canada, H3G 1A4
- GSK Clinical Trials Call Center
-
Saint-Foy, Quebec, Canada, G1V 4G2
- GSK Clinical Trials Call Center
-
-
-
-
-
Lagny sur Marne, France, 77400
- GSK Clinical Trials Call Center
-
Paris, France, 75475
- GSK Clinical Trials Call Center
-
Paris, France, 75970
- GSK Clinical Trials Call Center
-
Paris, France, 93009
- GSK Clinical Trials Call Centre
-
Saint Denis, France, 93205
- GSK Clinical Trials Call Center
-
Strasburg, France, 67000
- GSK Clinical Trials Call Center
-
Toulon, France, 83000
- GSK Clinical Trials Call Center
-
Vanouvre Les Nancy, France, 54511
- GSK Clinical Trials Call Center
-
-
-
-
-
Hamburg, Germany, 20095
- GSK Clinical Trials Call Center
-
-
-
-
-
Athens, Greece, 10676
- GSK Clinical Trials Call Center
-
Athens, Greece, 11526
- GSK Clinical Trials Call Center
-
Athens, Greece, 11527
- GSK Clinical Trials Call Center
-
Piraeus, Greece, 18536
- GSK Clinical Trials Call Center
-
-
-
-
-
Liguria, Italy, 16128
- GSK Clinical Trials Call Center
-
Lombardia, Italy, 27100
- GSK Clinical Trials Call Center
-
Romagna, Italy, 44100
- GSK Clinical Trials Call Center
-
Rome, Italy, 00 168
- GSK Clinical Trials Call Center
-
Torino, Italy, 10149
- GSK Clinical Trials Call Centre
-
Toscana, Italy, 50126
- GSK Clinical Trials Call Center
-
Toscana, Italy, 50139
- GSK Clinical Trials Call Center
-
Veneto, Italy, 35128
- GSK Clinical Trials Call Center
-
-
-
-
-
Barcelona, Spain, 8025
- GSK Clinical Trials Call Center
-
Jerez de la Frontera, Spain, 11407
- GSK Clinical Trials Call Center
-
Madrid, Spain, 28029
- GSK Clinical Trials Call Center
-
Madrid, Spain, 28040
- GSK Clinical Trials Call Center
-
Madrid, Spain, 28041
- GSK Clinical Trials Call Center
-
-
-
-
-
Birmingham, United Kingdom, B29 JD6
- GSK Clinical Trials Call Center
-
Brighton, United Kingdom, BN2 3EW
- GSK Clinical Trials Call Center
-
London, United Kingdom, EC1A 7BE
- GSK Clinical Trials Call Center
-
London, United Kingdom, NW3 2QG
- GSK Clinical Trials Call Center
-
London, United Kingdom, SE5 9RS
- GSK Clinical Trials Call Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Multiple protease-inhibitors experienced HIV-1 infected individuals experiencing virological failure and who's virus is not fully resistant to boosted fosamprenavir and boosted lopinavir based on genotypic resistance tests.
Exclusion criteria:
- No full resistance to FPV/r or LPV/r
- Planned use of NNRTIs as part of the study salvage regimen
- Application of additional exclusion criteria as determined by physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The average area under the curve minus baseline [AAUCMB] in plasma HIV-1 RNA at 24 Weeks when each are administered in combination with an optimised background therapy, in a multiple PI-experienced population experiencing virological failure.
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy (AAUCMB) at 48 weeks, safety, tolerability(incidence and nature of AEs and laboratory abnormalities) at week 24 and 48, CD4 change from baseline at week 24 and 48, and the steady-state plasma APV and LPV through concentrations.
Time Frame: 48 weeks
|
48 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
- Lopinavir
- Fosamprenavir
Other Study ID Numbers
Other Study ID Numbers
- APV102002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.